Viking Thera (VKTX) Stock Price, Quote & News

Company Profile

Viking Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of novel therapies for metabolic and endocrine disorders. Its lead drug candidate is VK2809, an orally available tissue and receptor-subtype selective agonist of the thyroid hormone receptor beta (TRß), which is in Phase IIb clinical trials to treat patients with biopsy-confirmed non-alcoholic steatohepatitis, as well as NAFLD. The company develops VK5211, an orally available non-steroidal selective...

Industry: Biotechnology

Sector: Healthcare

Phone: 858 704 4660

Website: www.vikingtherapeutics.com

Address:

9920 Pacific Heights Boulevard, Suite 350, San Diego, United States

Randini May. 13 at 3:27 PM

$VKTX this stock is so quiet... Volume of 260k at this time of day is ridiculous ... One of these days we're going to get back to our 5-7 million average volume

0 · Reply

Mark7531 May. 13 at 2:57 PM

$VKTX This stock is so underpriced its a joke. After maintenance trails in a couple of months I think it will blow up. especially if it showed the 20% or higher WL and the ”exceptional” tolerability BL is talking about.

0 · Reply

BioRich May. 13 at 2:48 PM

$XBI Hope y'all listened about $GUTS. My #1 Bio and #1 Overall. Truly transformational opportunity to shake-up the Obesity sector...not just in potentially replacing existing therapies (that's not our focus right now), but how it can supplement existing GLP-1s. $GUTS provides the treatment that allows GLP-1 users to keep the weight off following GLP-1 discontinuation. 1 time procedure and people are keeping the weight off. Follow/Subscribe for more suggestions and perspective. Would love to hear yours too. That' show we find these gems and learn. Let's make some (more) money. Cheers! #FractylForward $LLY $NVO $VKTX

0 · Reply

Wal187 May. 13 at 2:33 PM

$VKTX Who knows where the price of peptides will be in 2- 3 years. It seems like they will come down drastically. Can't understand why we wouldn't run the 90 and 120 arm in p3. At least have it available if prices do drop enough to make it economical.

2 · Reply

saifnila2 May. 13 at 2:07 PM

$VKTX traveling to turkey to present a crappy useless paper. Its called corporate vacation and tourism on the back of investors.

0 · Reply

saifnila2 May. 13 at 2:06 PM

$VKTX despicable pos. Will be waiting for a long time. Zero volume. Even the fuc king manipulators can't make any money on zero volume.

0 · Reply

Kylenorth May. 13 at 2:05 PM

$VKTX loser companies always lose especially with greedy management!!! they all will get their pay packages and will start selling more

1 · Reply

NYG4ever May. 13 at 1:56 PM

$VKTX another day closer - just another reason to buy more in the 20s

0 · Reply

IamCharlieSheen May. 13 at 1:46 PM

$VKTX revisit to $29.99 or over 32.32? we will know soon enough

0 · Reply

Kylenorth May. 13 at 1:41 PM

$VKTX bulls how come you go down with the market but not up?

1 · Reply

Viking Therapeutics’ VK2735 demonstrates wieght loss in Phase 2 trial

May 12, 2026, 7:05 AM EDT - 1 day ago

Viking Therapeutics Presents Data from its 13-Week Phase 2 VENTURE-Oral Dosing Trial of VK2735 at European Congress on Obesity (ECO) 2026

ECO

May 5, 2026, 7:05 AM EDT - 8 days ago

Viking Therapeutics Announces Two Poster Presentations at European Congress on Obesity (ECO) 2026

ECO

2026-05-04T16:05:12.000Z - 8 days ago

Viking Therapeutics call volume above normal and directionally bullish

2026-04-30T17:16:19.000Z - 12 days ago

Viking Therapeutics price target lowered to $100 from $105 at Cantor Fitzgerald

2026-04-30T14:12:18.000Z - 13 days ago

Viking Therapeutics price target lowered to $95 from $99 at Morgan Stanley

2026-04-29T21:38:53.000Z - 13 days ago

Viking Therapeutics reports Q1 EPS ($1.37), consensus (91c)

Apr 29, 2026, 4:30 PM EDT - 13 days ago

Viking Therapeutics Earnings Call Transcript: Q1 2026

Apr 29, 2026, 4:05 PM EDT - 13 days ago

Viking Therapeutics Reports First Quarter 2026 Financial Results and Provides Corporate Update

2026-04-29T18:51:37.000Z - 13 days ago

Viking Therapeutics options imply 7.0% move in share price post-earnings

Apr 22, 2026, 4:35 PM EDT - 20 days ago

Viking Therapeutics to Report Financial Results for First Quarter 2026 on April 29, 2026

Apr 10, 2026, 7:30 AM EDT - 4 weeks ago

Viking Therapeutics to Participate at Upcoming Investor Conferences

2026-04-09T18:25:15.000Z - 4 weeks ago

Viking Therapeutics call volume above normal and directionally bullish

2026-03-26T11:11:25.000Z - 6 weeks ago

Viking Therapeutics completes enrollment in Phase 3 VANQUISH-2 trial of VK2735

Mar 26, 2026, 7:05 AM EDT - 6 weeks ago

Viking Therapeutics Announces Completion of Enrollment in Phase 3 VANQUISH-2 Trial of VK2735

Mar 10, 2026, 10:40 AM EDT - 2 months ago

Viking Therapeutics Transcript: Leerink Global Healthcare Conference 2026

2026-03-03T17:37:55.000Z - 2 months ago

Viking Therapeutics management to meet with Truist

2026-02-23T17:07:01.000Z - 2 months ago

Viking Therapeutics rises 10.7%

2026-02-23T14:46:56.000Z - 2 months ago

Unusually active option classes on open February 23rd

FRO FSLY GRAL OPEN QUBT SLS VNDA

2026-02-12T13:20:55.000Z - 3 months ago

Viking Therapeutics price target lowered to $99 from $102 at Morgan Stanley

Feb 11, 2026, 5:10 PM EST - 3 months ago

Viking Therapeutics plans to advance oral obesity drug to late-stage trial

Feb 11, 2026, 4:30 PM EST - 3 months ago

Viking Therapeutics Earnings Call Transcript: Q4 2025

2026-02-11T21:28:43.000Z - 3 months ago

Viking Therapeutics reports Q4 EPS ($1.38), consensus (90c)

Feb 11, 2026, 4:16 PM EST - 3 months ago

Viking Therapeutics Reports Fourth Quarter and Year-End 2025 Financial Results and Provides Corporate Update

2026-02-11T19:20:16.000Z - 3 months ago

Viking Therapeutics options imply 9.5% move in share price post-earnings

Feb 4, 2026, 4:05 PM EST - 3 months ago

Viking Therapeutics to Report Financial Results for Fourth Quarter and Year-End 2025 on February 11, 2026

Feb 3, 2026, 1:27 PM EST - 3 months ago

Obesity stocks slump on Novo's underwhelming 2026 sales forecast

ALT AMGN GPCR LLY NVO PFE

2026-01-21T14:30:26.000Z - 4 months ago

Viking Therapeutics management to meet virtually with Oppenheimer

2026-01-14T18:05:20.000Z - 4 months ago

Novo Nordisk’s renewed M&A appetite sends obesity-drug names higher

GPCR LLY NVO PFE TERN

Jan 12, 2026, 7:19 PM EST - 4 months ago

Appetite for weight-loss deals broader than visible, Viking CEO says

Jan 12, 2026, 5:15 PM EST - 4 months ago

Viking Therapeutics Transcript: 44th Annual J.P. Morgan Healthcare Conference

Jan 12, 2026, 7:00 AM EST - 4 months ago

Viking Therapeutics Announces Publication of Results from Phase 2 VENTURE Trial of Dual GLP-1/GIP Receptor Agonist VK2735 in the Journal Obesity

Jan 8, 2026, 7:00 AM EST - 4 months ago

Viking Therapeutics Announces Completion of Enrollment in Maintenance Dosing Clinical Trial of VK2735 in Obesity

Jan 7, 2026, 7:00 AM EST - 4 months ago

Viking Therapeutics Announces Appointment of Neil Aubuchon as Chief Commercial Officer

Jan 5, 2026, 4:03 PM EST - 4 months ago

Viking Therapeutics to Present at the 44th Annual J.P. Morgan Healthcare Conference

Jan 5, 2026, 10:57 AM EST - 4 months ago

Novo Nordisk's weight-loss pill is available. Here's why Lilly's and Viking's stocks are down.

LLY NVO

Nov 25, 2025, 4:05 PM EST - 6 months ago

Viking Therapeutics to Participate at the Piper Sandler 37th Annual Healthcare Conference

Nov 19, 2025, 3:00 AM EST - 6 months ago

Viking Therapeutics Transcript: Jefferies London Healthcare Conference 2025

Nov 19, 2025, 2:55 AM EST - 6 months ago

Viking Therapeutics Announces Completion of Enrollment in Phase 3 VANQUISH-1 Trial of VK2735

Nov 6, 2025, 7:05 AM EST - 6 months ago

Viking Therapeutics Highlights Clinical Data from VK2735 Obesity Program in Presentation at ObesityWeek® 2025

Oct 29, 2025, 4:05 PM EDT - 6 months ago

Viking Therapeutics to Highlight Clinical Data from VK2735 Obesity Program in Presentations at ObesityWeek® 2025

Oct 22, 2025, 4:30 PM EDT - 7 months ago

Viking Therapeutics Earnings Call Transcript: Q3 2025

Oct 22, 2025, 4:05 PM EDT - 7 months ago

Viking Therapeutics Reports Third Quarter 2025 Financial Results and Provides Corporate Update

Oct 21, 2025, 7:05 AM EDT - 7 months ago

Viking Therapeutics Announces Initiation of VK2735 Maintenance Dosing Clinical Trial in Patients with Obesity

Oct 15, 2025, 4:05 PM EDT - 7 months ago

Viking Therapeutics to Report Financial Results for Third Quarter 2025 on October 22, 2025

Sep 23, 2025, 11:20 AM EDT - 8 months ago

Viking Therapeutics Transcript: Bernstein Insights: Healthcare Leaders and Disruptors - 2nd Annual Healthcare Forum

Sep 8, 2025, 3:20 PM EDT - 8 months ago

Viking Therapeutics Transcript: Morgan Stanley 23rd Annual Global Healthcare Conference

Aug 20, 2025, 9:50 AM EDT - 9 months ago

Viking Therapeutics: What's Happening With VKTX Stock?

Aug 19, 2025, 9:38 PM EDT - 9 months ago

Why Viking Therapeutics stock reaction to obesity pill data is wildly ‘overdone'

Aug 19, 2025, 6:27 PM EDT - 9 months ago

Mizuho's Jared Holz talks Viking Therapeutics' massive stock drop on obesity pill data

Aug 19, 2025, 1:45 PM EDT - 9 months ago

The market reaction is overdone on Viking Therapeutics, says BTIG's Justin Zelin

Aug 19, 2025, 12:19 PM EDT - 9 months ago

Viking Therapeutics plummets on new obesity drug data. Here's a breakdown

Aug 19, 2025, 12:05 PM EDT - 9 months ago

Viking Therapeutics Stock Plunges on Oral Weight-Loss Pill Study Results

Aug 19, 2025, 11:00 AM EDT - 9 months ago

Viking Therapeutics Shares Nosedive Toward Worst Day Ever After Obesity Trial Data

Aug 19, 2025, 9:39 AM EDT - 9 months ago

Viking Therapeutics shares fall more than 30% on disappointing obesity pill trial data

Aug 19, 2025, 9:11 AM EDT - 9 months ago

Viking Therapeutics' stock tumbles after results of oral weight-loss drug trial. It has company.

Aug 19, 2025, 8:57 AM EDT - 9 months ago

Viking Therapeutics stock tumbles 37% today, but here's why you should ‘HOLD'

Aug 19, 2025, 8:00 AM EDT - 9 months ago

Viking Therapeutics Transcript: Study Result

Aug 19, 2025, 7:18 AM EDT - 9 months ago

Viking Therapeutics' oral weight-loss pill meets expectations in mid-stage study

Aug 19, 2025, 7:08 AM EDT - 9 months ago

Viking Therapeutics Announces Positive Top-Line Results from Phase 2 VENTURE-Oral Dosing Trial of VK2735 Tablet Formulation in Patients with Obesity

Jul 23, 2025, 4:30 PM EDT - 10 months ago

Viking Therapeutics Earnings Call Transcript: Q2 2025

Jul 23, 2025, 4:05 PM EDT - 10 months ago

Viking Therapeutics Reports Second Quarter 2025 Financial Results and Provides Corporate Update

Jul 16, 2025, 4:05 PM EDT - 10 months ago

Viking Therapeutics to Report Financial Results for Second Quarter 2025 on July 23, 2025

Jun 25, 2025, 7:03 AM EDT - 11 months ago

Viking Therapeutics Announces Initiation of Phase 3 Obesity Clinical Program with GLP-1/GIP Agonist VK2735

Jun 23, 2025, 6:10 PM EDT - 11 months ago

Pharma companies need to beef up M&A right now, says Mizuho's Jared Holz

AMGN GPCR LLY NVO PFE REGN XBI

Jun 5, 2025, 11:40 AM EDT - 1 year ago

Viking Therapeutics Transcript: Jefferies Global Healthcare Conference 2025

Apr 23, 2025, 4:30 PM EDT - 1 year ago

Viking Therapeutics Earnings Call Transcript: Q1 2025

Apr 23, 2025, 4:05 PM EDT - 1 year ago

Viking Therapeutics Reports First Quarter 2025 Financial Results and Provides Corporate Update

Apr 15, 2025, 3:26 PM EDT - 1 year ago

Will Pfizer approach Viking Therapeutics with a buyout proposal?

Mar 26, 2025, 7:05 AM EDT - 1 year ago

Viking Therapeutics Announces Completion of Enrollment in Phase 2 VENTURE-Oral Dosing Trial of VK2735 Tablet Formulation in Patients with Obesity

Mar 12, 2025, 11:54 AM EDT - 1 year ago

Viking Therapeutics' new contract is a game changer. Here's how much money it could bring in.

Mar 11, 2025, 9:20 AM EDT - 1 year ago

Viking Therapeutics Transcript: Leerink’s Global Healthcare Conference 2025

Mar 11, 2025, 7:03 AM EDT - 1 year ago

Viking Therapeutics Signs Broad Manufacturing Agreement With CordenPharma to Support Commercialization of VK2735

Feb 5, 2025, 4:30 PM EST - 1 year ago

Viking Therapeutics Earnings Call Transcript: Q4 2024

Feb 5, 2025, 4:05 PM EST - 1 year ago

Viking Therapeutics Reports Fourth Quarter and Year-End 2024 Financial Results and Provides Corporate Update

Jan 29, 2025, 4:05 PM EST - 1 year ago

Viking Therapeutics to Report Financial Results for Fourth Quarter and Year-End 2024 on February 5, 2025

Jan 23, 2025, 7:38 AM EST - 1 year ago

Why this Weight-Loss Drug Stock Could Gain 200%

Jan 21, 2025, 3:04 PM EST - 1 year ago

What's next for Viking Therapeutics? Here's how the company can scale up.

Jan 13, 2025, 4:30 PM EST - 1 year ago

Viking Therapeutics Transcript: 43rd Annual J.P. Morgan Healthcare Conference 2025

Jan 8, 2025, 7:03 AM EST - 1 year ago

Viking Therapeutics Announces Initiation of Phase 2 VENTURE-Oral Dosing Trial of VK2735 Tablet Formulation in Patients with Obesity

Randini May. 13 at 3:27 PM

$VKTX this stock is so quiet... Volume of 260k at this time of day is ridiculous ... One of these days we're going to get back to our 5-7 million average volume

0 · Reply

Mark7531 May. 13 at 2:57 PM

0 · Reply

BioRich May. 13 at 2:48 PM

0 · Reply

Wal187 May. 13 at 2:33 PM

2 · Reply

saifnila2 May. 13 at 2:07 PM

$VKTX traveling to turkey to present a crappy useless paper. Its called corporate vacation and tourism on the back of investors.

0 · Reply

saifnila2 May. 13 at 2:06 PM

$VKTX despicable pos. Will be waiting for a long time. Zero volume. Even the fuc king manipulators can't make any money on zero volume.

0 · Reply

Kylenorth May. 13 at 2:05 PM

$VKTX loser companies always lose especially with greedy management!!! they all will get their pay packages and will start selling more

1 · Reply

NYG4ever May. 13 at 1:56 PM

$VKTX another day closer - just another reason to buy more in the 20s

0 · Reply

IamCharlieSheen May. 13 at 1:46 PM

$VKTX revisit to $29.99 or over 32.32? we will know soon enough

0 · Reply

Kylenorth May. 13 at 1:41 PM

$VKTX bulls how come you go down with the market but not up?

1 · Reply

Kylenorth May. 13 at 1:38 PM

$VKTX down down down!!!

1 · Reply

NetworkNewsWire May. 13 at 1:19 PM

Next-Generation GLP-1 Innovation Could Unlock Massive Metabolic Healthcare Market Opportunities $SURE.CN $SURNF $MRK $ABBV $VKTX $ALT https://ibn.fm/xuvoa

0 · Reply

Stockman824 May. 13 at 12:34 PM

$VKTX vanguard so far in Q1 has added over 10 million new shares. Not everyone has reported yet https://www.nasdaq.com/market-activity/stocks/vktx/institutional-holdings

0 · Reply

Thehighpriestess420 May. 13 at 12:19 PM

$VKTX my biggest under performer for years now. Dragging feet

1 · Reply

DG20 May. 13 at 6:25 AM

$VKTX Let’s set this straight, you shouldn’t be giving medical advice and posts on social media do not constitute facts. Theoretically, glucagon spares muscle but there’s not a ton of clinical evidence that bears that out. Glucagon does however worsen nausea/vomiting, add palpitations/dysesthsias and worsen A1C control versus Tirzepatide. FYI, Retatrutide isn’t FDA approved yet so those using it are technically buying from a black/grey market. Also, many of the community doing Reta are also on Testosterone or SARMs. The fitness industry is full of a lot of people who are doping if you weren’t aware. There is nothing to date to suggest that Retatrutide spares significant lean mass (ie skeletal muscle) vs other GLPs. Here’s some actual facts from Lancet…

1 · Reply

DG20 May. 13 at 4:02 AM

$VKTX PO effectively validated SQ, no single molecule comes close in WL for both forms of administration outside of Amycretin and its side effect profile is atrocious. VK2735 works extremely well…

0 · Reply

biolover May. 13 at 3:59 AM

$VKTX I am surprised amylin trial has not started yet. BL was waiting for FDA cleaned which is in 30 days. This is him in March “ as soon as IND clears “

3 · Reply

parrotineum May. 13 at 2:33 AM

$VKTX correct me if i’m wrong but I don’t recall corporate presentation previously having row specifying TEAE leading to study discontinuation in Oral Phase 2. How is this not getting more attention? 0% DC in multiple dosages. Only 2 total people discontinued out of 200 people = 1% discontinued in whole study due to treatment related adverse events. Comparatively Structure now looks incredibly intolerable. Looks like within presentstio they specify amylin phase 1 to start 2H26 and Oral Phase 3 planned 4Q26.

1 · Reply

Mrup25 May. 13 at 2:12 AM

$VKTX sinking ship pile of dogshit . the last time they had decent data was 2 years ago w an early pre dawn spike to $85. cratered 10 minutes later. its a CSuite mess

1 · Reply

NYG4ever May. 13 at 2:06 AM

$VKTX tight like a tiger

0 · Reply

IamCharlieSheen May. 13 at 1:35 AM

$VKTX I mean can the trading range get any tighter ?

0 · Reply

SlimyMango May. 13 at 1:05 AM

$VKTX The lion does not concern himself with the daily fluctuations of future blockbuster VKTX

0 · Reply

Market Cap	3.68B
Revenue (ttm)	0.00
Net Income (ttm)	-359.64M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	0.00%
Debt to Equity Ratio	0.00

Volume	1,328,400
Avg Vol	2,366,894
Day's Range	N/A - N/A
Shares Out	116.11M
Stochastic %K	65%
Beta	0.72
Analysts	Strong Sell
Price Target	$91.94